EANS-DD: AGENNIX AG
Notification concerning transactions by persons performing
managerial responsibilities pursuant to section 15a of the WpHG
-------------------------------------------------------------------------------- Notification concerning transactions by persons discharging managerial responsibilities pursuant to section 15a of the WpHG, transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------
Details of the person subject to the disclosure requirement: --------------------------------------------------------------------------------
Person, triggering the disclosure: ----------------------------- Name: dievini Hopp BioTech holding GmbH & Co. KG (Legal person, company or institution)
Reason for the disclosure requirement: ------------------------------ Reason: Legal person, company or institution closely associated Relationship: To a person performing managerial responsibilities
Person performing managerial responsibilities, triggering the disclosure requirement:
-------------------------------------------------------------------------------- Position: Member of an administrative or supervisory body Details of the transaction: -------------------------------------------------------------------------------- Transaction: ------------ Description of financial instrument: no par value ordinary bearer shares ISIN: DE000A1A6XX4 Type of transaction: purchase Date: 27.10.2010 Currency: Euro Price: non-numeric No of items: 600000 Place: OTC Explanation: Price: EUR 0,00 Volume: EUR 1,00 The shares were purchased from James D. Weaver III, Margaret W. Weaver, Cain Asset Management LLC, Cain Investments Limited L.P. and certain others persons (together the Cain Shareholders) in connection with the subscription for shares by dievini Hopp BioTech holding GmbH & Co. KG in the course of the capital increase of Agennix AG. The purchase by dievini Hopp BioTech holding GmbH & Co. KG is attributed to the named members of the managing and supervisoring bodies (Prof. von Bohlen und Halbach as a member of the Management Board and Prof. Hettich as a member of the Supervisory Board).
Further inquiry note: ----------------- Investor Relations & Corporate Communications Tel.: +49 (0) 89 8565 2693 E-Mail: ir@agennix.com
Issuer subject to the publication requirement: --------------------------------------------------------------------------------
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade
Original content of: AGENNIX AG i.L., transmitted by news aktuell